Why Nobilis Health, Sunrun, Luxoft Holding and Two Other Stocks Are Surging Today?

Page 1 of 2

Markets are headed to conclude the week on a disappointing note after bad retail sector data for April dented the investor sentiment on Friday morning. However, some of the stocks are still flying high today, including Nobilis Health Corp (USA) (NYSEMKT:HLTH), Oramed Pharmaceuticals, Inc. (NASDAQ:OMP), Momo Inc (ADR) (NASDAQ:MOMO), Sunrun Inc (NASDAQ:RUN), and Luxoft Holding Inc (NYSE:LXFT). In this article, we are going to take a look at why these stocks are gaining ground today along with an analysis of hedge funds sentiment towards them.

Academic research has shown that certain insider purchases historically outperformed the market by an average of seven percentage points per year. This effect is more pronounced in small-cap stocks. Another exception is the small-cap stock picks of hedge funds. Our research has shown that imitating the 15 most popular small-cap stocks among hedge funds outperformed the market by nearly a percentage point per month between 1999 and 2012 (read more details here).

Nobilis Health Beats Revenue Estimates

Nobilis Health Corp (USA) (NYSEMKT:HLTH)’s stock skyrocketed by more than 18% today after the company released its first-quarter earnings report, beating the revenue estimates. The Houston-based health company’s revenue increased 35% year-over-year to $51.27 million, versus the consensus of $ 43.15 million, while net loss of $0.07 per share, missed the estimates of a profit of $0.01 per share. For full fiscal 2016, the company reaffirmed its revenue of $320 million, above the Street’s expectation of $312.2 million. In the earnings call, Nobilis Health’s CEO, Harry Fleming, said that the company invested heavily in the new technology and infrastructure to increase its growth in 2016 and that Nobilis is still going through the aftermath of the October short attack. Only six funds from our database had stakes in Nobilis Health Corp (USA) (NYSEMKT:HLTH) at the end of 2015, unchanged from the quarter earlier.

Oramed Pharmaceuticals’ Project Gets Patent in China

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP)’s stock continues to gain heavily after it announced that China’s State Intellectual Property had granted a patent right for its proposed invention titled  “Oral Administrations of Proteins.” This project is regarding the treatment of diabetes using an orally-ingestible insulin capsule. Shares of Oramed Pharmaceuticals have soared by more than 13% so far today. At the end of last year, Israel Englander’s Millennium Management owned 14,364 shares of  Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP).

Follow Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

On the next page, we will discuss the events surrounding Momo, Sunrun and Luxoft. 

Page 1 of 2